- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal, Adverse events: Immunogenicity and adverse events of SARS-CoV-2 vaccine in health workers (Pubmed Central) - Jun 22, 2024
Mass vaccination and administration of the recommended dose are essential to achieve effective herd immunity. The majority of vaccinated healthcare workers developed antibodies and those who had the disease prior to vaccination had significant antibody titers.
- |||||||||| Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm, Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
LONG-TERM SAFETY OF VACCINATION FOR COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES AND PSORIASIS: DATA FROM THE SAR-CoVAC REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_3881;
Regarding the primary vaccination regimen, the most frequently used vaccines were Gam-COVID-Vac, ChAdOx1 nCoV-19 and BBIBP-CorV, mostly in the form of homologous regimens (67.2%). In this cohort in which the COVID-19 vaccines available in our country were evaluated, they proved to be safe in patients with RD and/or Ps.
- |||||||||| CoronaVac / Sinovac, Bio Farma Indonesia, Comirnaty (tozinameran) / Pfizer, BioNTech, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Observational data, Journal: Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina. (Pubmed Central) - May 29, 2024
Infection both before vaccination and after the booster dose, and Gam-COVIDVac + BNT162b2 combination correlated with higher antibody titers. The sole predictor of infection in the six-month follow-up was a prior COVID-19 infection before the vaccination scheme, which decreased the risk of infection, and all booster vaccine combinations conveyed the same amount of protection.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination. (Pubmed Central) - May 28, 2024
The dissection of the Ab reactivity to different regions of S allowed us to identify the relevance of epitopes outside the RBD that are able to induce NAbs. This research may contribute to the understanding of vaccine immunity against SARS-CoV-2, which could contribute to the design of future vaccine strategies.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally. (Pubmed Central) - Apr 24, 2024
No significant differences have been observed regarding the overall performance across five vaccines (QazVac, Sputnik V, CoronaVac, Hayat-Vax, and BioNTech/Pfizer) available for Kazakhstan's population (p 0.27). The majority evaluated vaccines primarily used in high-income countries: Pfizer BioNTech (Comirnaty; n
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities (Exhibit Hall F1; Poster Board Number: B179) - Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_1663;
The Ad26/Ad5-induced antibodies also showed a greater potency of binding Fcgamma receptors than those of the other two groups. Hence, antibodies of different Ig isotypes/subtypes and with greater Fc activities were elicited by COVID-19 vaccines, highlighting the distinctive quality of antibodies induced by vaccination versus virus infection.
- |||||||||| Journal: Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines. (Pubmed Central) - Mar 28, 2024
The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light...Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination.
- |||||||||| Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
THE USE OF MONOCLONAL ANTIBODIES (TIXAGEVIMAB AND CIGLAVIMAB) FOR PREEXPOSURE PROPHYLAXIS OF SEVERE COVID-19 INFECTION IN PATIENTS ON HEMODIALYSIS (MON-236; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1419;
Hence, antibodies of different Ig isotypes/subtypes and with greater Fc activities were elicited by COVID-19 vaccines, highlighting the distinctive quality of antibodies induced by vaccination versus virus infection. The Evusheld showed no specific antiviral activity against the new COVID-19 strains, but was effective in preventing severe cases of infection, possibly due to a significant increase in titers of IgG specific to the receptor-binding domain of the SARS-CoV-2 virus.
- |||||||||| CoronaVac / Sinovac, Bio Farma Indonesia, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
COMPARATIVE ANALYSIS OF THE COVID-19 COURSE IN THE KIDNEY TRANSPLANT RECIPIENTS DURING DIFFERENT EPIDEMIOLOGICAL PERIODS (MON-119; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_969;
The Evusheld showed no specific antiviral activity against the new COVID-19 strains, but was effective in preventing severe cases of infection, possibly due to a significant increase in titers of IgG specific to the receptor-binding domain of the SARS-CoV-2 virus. The results of the study revealed a change in disease severity, with a shift towards milder forms, and the number of COVID-19 deaths reached zero by the end of the follow-up period.
- |||||||||| Sputnik Light / Gamaleya Research Institute
Disparities in Anti-SARS-CoV-2 Reactivity According to Vaccines in the Era of Omicron in Cameroon (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_158;
Regarding COVID-19 vaccination, 67.5%(1652/2449) had received at least one dose (48.7% Pfizer, 24.8% Johnson&Johnson, 18.2% Moderna; 8.1% AstraZeneca, 4.8% Sinopharm and 0.2% Sputnik-light); among these, 55.0%(909/1652) were fully vaccinated and 37.1%(613/1652) received additional boost doses...The high-rate of COVID-19 antibodies suggests herd immunity at community-level in Cameroon, during the wide circulation of Omicron. Furthermore, vaccination with Pfizer appears with higher Covid-19 antibody response, supporting the need for vaccine update with novel variants, especially with the rapid antibody weaning (~5months) in this tropical setting.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Observational data, Journal, Adverse events: Evaluation of short-term adverse events of COVID-19 vaccines: An observational study. (Pubmed Central) - Feb 27, 2024
The most commonly reported AEs were injection site pain (local) and fatigue and lethargy (systemic). These expected AEs occurred shortly after vaccination and indicated an early immune response after vaccination.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Clinical, Journal, Adverse events: Short-term side effects of COVID-19 vaccines among healthcare workers: a multicenter study in Iran. (Pubmed Central) - Feb 24, 2024
In conclusion, according to the COVID-19 vaccine type, different side effects might occur following the first and second doses of vaccination. These findings assist in addressing the ongoing problems of vaccination hesitancy which has been driven by widespread worries about the vaccine safety profile.
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Immune response to SARS-CoV-2 variants after immunization with different vaccines in Mexico. (Pubmed Central) - Feb 20, 2024
These findings assist in addressing the ongoing problems of vaccination hesitancy which has been driven by widespread worries about the vaccine safety profile. Here, we analysed the immunogenicity of homologous schemes using the ChAdOx1-S, Sputnik V, or BNT162b2 vaccines and the effect of a booster dose with ChAdOx1-S in middle-aged adults who were seropositive or seronegative to the SARS-CoV-2 spike protein before vaccination...No abstract available
- |||||||||| Sputnik Light / Gamaleya Research Institute
Observational data, Journal, Adverse events: Assessing the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults: A cross-sectional study. (Pubmed Central) - Jan 29, 2024
This study aimed to assess the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults, with a focus on the AstraZeneca and Sputnik Light vaccines, in light of the low vaccination rate in Syria (below 18%) attributed to fear of side effects...Our study found that COVID-19 vaccines are well tolerated among the Syrian population, with short-term side effects that typically resolve within three days. These findings are expected to bolster vaccination rates through enhanced public confidence and acceptance.
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia. (Pubmed Central) - Dec 8, 2023
A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.
- |||||||||| Journal, Real-world evidence, Real-world effectiveness, Real-world: Assessing the real-world effectiveness of five SARS-CoV-2 vaccines in a cohort of Mexican pensioners: a nationwide nested test-negative design study. (Pubmed Central) - Oct 27, 2023
We aimed to evaluate the effectiveness of five vaccines (BNT162b2, AZD1222, CoronaVac, Gam-COVID-Vac, and Ad5-nCoV) in a cohort of 2,559,792 pensioners covered by the Mexican Institute of Social Security...All five SARS-CoV-2 vaccines available for this population showed moderate to high levels of protection against COVID-19 and its progression to severe outcomes. Fundaci
- |||||||||| Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm, Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca
Journal: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study. (Pubmed Central) - Oct 9, 2023
During omicron predominance, heterologous boosters such as viral vectored and mRNA vaccines, following Sputnik V, ChAdOx1, Sinopharm or heterologous primary schemes might provide better protection against death; this effect might last longer in individuals aged ?50 than homologous boosters. None.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: The Features of COVID-19's Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria. (Pubmed Central) - Sep 27, 2023
The study included data from 52 patients with PNH aged 18 to 75 years, 38 of whom received background therapy with eculizumab (Elizaria) between March 2020 and January 2022...After the second dose, no AEs were reported. The performed study suggests the possible efficacy and demonstrates the safety of Gam-COVID-Vac (Sputnik V) for the prophylaxis of COVID-19 in patients with PNH who experience immunosuppression due to target therapy.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study. (Pubmed Central) - Aug 25, 2023
P2/3
Higher dose resulted in increased cross-neutralization of Delta and Omicron variants. ClinicalTrials.gov, NCT04954092, LP-007632.
- |||||||||| Journal: Humoral and T-cell response to SARS-CoV-2 vaccination in patients with rheumatoid arthritis. (Pubmed Central) - Aug 22, 2023
In this RA cohort vaccinated with homologous and heterologous regimens against COVID-19, two out of ten patients did not develop IgG anti-SARS-CoV-2, 70% presented neutralizing activity and 65% specific T-cell response. The use of BBIBP-CorV was associated with deficient humoral and cellular response, while treatment with ABA and RTX resulted in an impaired IgG anti-SARS-CoV-2 formation and neutralizing activity.
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
A study on cutaneous adverse events of Covid Vaccine () - Jul 3, 2023 - Abstract #WCD2023WCD_3902;
Study included 52 subjects (Females 55%), 59.6% in 30-40 years age group, 93% had taken Covishield, 5% Covaxin and 2% Sputnik V. Time of onset of lesions after vaccination: In 55.7% within 7 days, 36.6% between 7 to 15 days and 7.7% between 15-30 days... The varied cutaneous adverse events post covid vaccination observed in our study and many similar studies published, makes it important to consider the possibility of covid vaccine related inflammatory and autoimmune phenomena.
- |||||||||| Ocrevus (ocrelizumab) / Roche, Biogen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Serological response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina. (Pubmed Central) - Jul 2, 2023
The varied cutaneous adverse events post covid vaccination observed in our study and many similar studies published, makes it important to consider the possibility of covid vaccine related inflammatory and autoimmune phenomena. We found that MS patients that received Sputnik V or AstraZeneca vaccines for SARS-CoV-2 developed a serological response with no differences between the vaccines used.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Catalase Activity of IgGs of Patients Infected with SARS-CoV-2. (Pubmed Central) - Jul 2, 2023
We here show that the IgGs from patients who recovered from COVID-19 had the highest catalase activity, and this was statistically significantly higher each compared to the healthy donors (1.9-fold), healthy volunteers vaccinated with Sputnik V (1.4-fold), and patients vaccinated after recovering from COVID-19 (2.1-fold). These data indicate that COVID-19 infection may stimulate the production of antibodies that degrade hydrogen peroxide, which is harmful at elevated concentrations.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal, PD(L)-1 Biomarker, IO biomarker: Phenotypic Changes in T and NK Cells Induced by Sputnik V Vaccination. (Pubmed Central) - Jun 28, 2023
A short-term elevation of the activating NKG2D and CD16 was observed in NK cells. Overall, the findings of the study are in favor of the Sputnik V vaccine not provoking a dramatic phenotypic rearrangement in T and NK cells, although it induces their slight temporal non-specific activation.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Reactive Arthritis after Gam-COVID-Vac Vaccination: A Case Report. (Pubmed Central) - Jun 21, 2023
Although the safety and efficacy of vaccinations have been evaluated through clinical trials, medical experts and authorities are very interested in the reporting and investigation of adverse events following SARS-CoV-2 immunization in the general public. This article reports a 41-year-old man without history of underlying diseases, complaining of continuous morning stiffness and acute discomfort in his left elbow joint, 20 days after taking the first dosage of Sputnik V. The case was extensively studied, and a possible diagnosis of reactive arthritis was made.
|
